ArticleBMC infectious diseases2026
Workflow-embedded automation improves hepatitis B screening and safety in b/tsDMARD users.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite guideline-mandated universal screening, adherence to hepatitis B virus (HBV) testing before the initiation of biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) remains suboptimal, placing patients at risk for HBV reactivation (HBVr).
methodsWe retrospectively studied 1,909 adults starting b/tsDMARD therapy from 2004 to 2024, comparing three stages: baseline (2004-2016), education (2017-2020), and work-flow-integrated (2021-2024). In the last stage, a workflow-embedded clinical decision support system (CDSS) was integrated into computerized order entry to automatically verify HBV serologic status and generate missing screening orders at the point of prescription. The outcomes assessed were pre-treatment HBV screening completion, monitoring frequency, and HBVr-related clinical events.
resultsHBV screening rates progressively improved across stages. HBsAg testing increased from 91% at baseline to 98% during the workflow integrated stage. Completion of the two-marker panel (HBsAg/anti-HBc) increased from 63% to 93%, whereas full three-marker panel testing increased from 47% to 90%. These process improvements were accompanied by a significant reduction in HBVr, which decreased from 5.2% to 1.5% (p < 0.001), and hepatitis flares, which decreased from 1.9% to 0.2% (p < 0.001). However, antiviral prophylaxis before b/tsDMARD initiation remains uncommon (4.2%) and HBV DNA monitoring is infrequently performed.
conclusionWorkflow-embedded CDSS led to almost universal HBV screening and notable reductions in HBV reactivation and flares. The remaining risk suggests that future systems should include automated long-term monitoring and better enforcement of prophylactic guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.